---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134303"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:10:14.595005+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Catalyst Q1 revenue $98.5M (+15.4% YoY); AGAMREE launch adds $1.2M

## Summary
- Total Q1 2024 net product revenue $98.5M, up 15.4% YoY; FIRDAPSE net revenue $66.8M (+16.2%).
- AGAMREE contributed $1.2M net revenue in first two weeks of U.S. launch, surpassing initial expectations.
- GAAP net income $23.3M ($0.19 diluted EPS); Non-GAAP net income $46.8M ($0.38 diluted EPS).
- Cash and cash equivalents $310.4M as of March 31, 2024, a 125.5% increase from year-end 2023.
- Full-year 2024 total revenue guidance reaffirmed at $455M-$475M.

## SEC filing metadata
- accession: 0001193125-24-134303
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524134303/0001193125-24-134303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524134303/d837068d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134303
- JSON: https://secwatch.observer/filing/0001193125-24-134303.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.